‚First in human‘ trial defines safe dosage for small molecule drug ONC201 for solid cancer tumors

A ‘first in human’ clinical trial examining the small molecule drug ONC201 in cancer patients with advanced solid tumors shows that this investigational drug is well tolerated at the recommended phase II dose. That’s according to investigators whose research also showed early signs of clinical benefit in patients with advanced prostate and endometrial cancers. (Mehr in: Cancer News — ScienceDaily)